Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|July 5, 2018

Improving Provider and Patient Acceptance of Biosimilars in Treating Cancer

https://www.pharmacytimes.org/on-demand/biosimilars-in-treating-cancer

https://www.pharmacytimes.org/on-demand/biosimilars-in-treating-cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Medicare Advantage Plans | Image Credit: @Andrii_AdobeStock.jpeg

Cancer Center Network Breadth Not Linked to Lower MA Disenrollment Rates

BySabrina McCrear

June 16th 2026

Wearable technology | Image credit: wichayada - stock.adobe.com

Wearables Play Pivotal Role in Diagnosing, Identifying OSA

ByJulia Bonavitacola

June 16th 2026

Health care costs and fees concept. Hand of doctor using a calculator for medical costs | Image credit: everythingpossible - stock.adobe.com

AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike

ByLaura Joszt, MA

June 16th 2026

Dermatomyositis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Patient-Reported Symptoms Reliably Signal True Disease Flares in Dermatomyositis

BySkylar Jeremias

June 16th 2026

Weight loss injections. | Image Credit: ricka_kinamoto - stock.adobe.com

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

ByGiuliana Grossi

June 15th 2026

Trending on AJMC

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

Type 5 Diabetes: A Long-Ignored Condition Gets Its Moment

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

CMS Proposes Permanent Rules for Medicare Drug Price Negotiation

CKD Stage, Proteinuria Tied to Higher HCRU in IgAN